Display options
Share it on

Br Med J (Clin Res Ed). 1981 May 30;282(6278):1744-5. doi: 10.1136/bmj.282.6278.1744.

Hepatic vascular lesions associated with dacarbazine treatment.

British medical journal (Clinical research ed.)

M A Greenstone, P M Dowd, D P Mikhailidis, P J Scheuer

PMID: 6786601 PMCID: PMC1505709 DOI: 10.1136/bmj.282.6278.1744

Abstract

Dacarbazine is widely used in the treatment of melanoma. Transient abnormalities of liver function tests are well-recognised side effects of the drug, but acute liver failure due to vascular occlusion in patients receiving single-agent chemotherapy with dacarbazine has been noted only rarely. Two cases are reported in which hepatic vascular lesions developed during treatment with dacarbazine and were confirmed at necropsy. Hepatic vascular occlusion due to treatment with dacarbazine may be less rare than was previously thought. Greater caution may be needed when dacarbazine is prescribed, particularly as an adjuvant agent in stage I and II disease.

Cited by

References

  1. Cancer Treat Rep. 1976 Feb;60(2):183-7 - PubMed
  2. Cancer. 1980 May 15;45(10):2670-4 - PubMed
  3. Cancer. 1979 Dec;44(6):2324-9 - PubMed
  4. Ann Intern Med. 1978 Apr;88(4):575-6 - PubMed

Substances

MeSH terms

Publication Types